Cargando…
EGFR-L861Q突变对TKI类药物敏感性预测分析及病例报道
BACKGROUND AND OBJECTIVE: The significant efficacy of tyrosine kinase inhibitors (TKIs) has been approved for advanced non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations. No clear evidence exists that EGFR-L861Q is sensitive to TKIs, and the...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000112/ https://www.ncbi.nlm.nih.gov/pubmed/26383985 http://dx.doi.org/10.3779/j.issn.1009-3419.2015.09.11 |